1. April 8, 2013
Asiatic Health News
Clinical trial:
A randomized controlled cross-over study of
Flupenthixol + Melitracen in Functional Dyspepsia.
BACKGROUND:
Functional dyspepsia is a prevalent condition associated with diminished quality of life (QoL)
and high economic burden.
AIM:
To study the efficacy of a combination of Flupenthixol and Melitracen (F+M) with anxiolytic
and antidepressant properties in functional dyspepsia using a randomized controlled cross-
over design.
74%
26%
Functional Dyspepsia
Placbo
Antison
(Flupenthixol + Melitracen)
RESULTS:
Twenty-five patients (14 females, 11 males; mean age = 34.3 +/- 9.9 years) were enrolled
and 24 completed the 8-week study. There was a significant improvement in subjective
global symptom relief with Flupenthixol + Melitracen vs. placebo (ITT: 73.9% vs. 26.1%, P =
0.001). No difference was noted whether the initial treatment was Flupenthixol + Melitracen
or placebo. No significant side effects were noted.
Ref: 1. Aliment Pharmacol Ther. 2008 Jun 1;27 (11): 1148-55.
CONCLUSIONS:
A combination of Flupenthixol and Melitracen is safe and effective in the short-term
treatment of functional dyspepsia. Flupenthixol + Melitracen is associated with significant
improvement in Quality of Life independent of the presence of Anxiety & Depression.
ITT=Intent to treat
Courtesy By Now available in Alu-Alu Blister
Flupentixol BP 0.5 mg + Melitracen INN 10 mg
A new dimension for treating Anxiety and Depression